PCVX Q3 2025 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$242M

Net Income

-$213M

EPS (Diluted)

$-1.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$143M

Free Cash Flow

-$155M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$3.2B

Total Liabilities

$279M

Stockholders' Equity

$2.9B

Cash & Equivalents

$281M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$242M	-$140M	-73.2%
Net Income	-$213M	-$103M	-106.4%